| Project/Area Number |
15K09949
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
川井 恵一 金沢大学, 保健学系, 教授 (30204663)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAMAI Ikumi 金沢大学, 薬学系, 教授 (20155237)
OKAZAWA Hidehiko 福井大学, 高エネルギー医学研究センター, 教授 (50360813)
KUNISHIMA Munetaka 金沢大学, 薬学系, 教授 (10214975)
NISHII Ryuichi 放射線医学総合研究所, 分子イメージング診断治療研究部, 主任研究員 (60463212)
SHIKANO Naoto 茨城県立医療大学, 保健医療学部, 准教授 (80295435)
NISHI Kodai 長崎大学, 原爆後障害医療研究所, 助教 (10719496)
|
|---|
| Research Collaborator |
INNIS B Robert National Institute of Mental Health, Molecular Imaging Branch, Chief
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 核医学 / 分子イメージング / 個別化治療 / 多剤耐性 / 薬物トランスポータ / 個別化医療 / SPECT / 小動物イメージング / トランスポータ / 抗がん剤 |
|---|
| Outline of Final Research Achievements |
We developed high an accuracy multidrug resistance prediction method using SPECT imaging for individualized anticancer therapy. Although [99mTc]sestamibi and [99mTc]tetrofosmin has been reported to be the same method, we clarified that [99mTc]sestamibi had affinity to MDR1 and MRP1, whereas [99mTc]tetrofosmin had affinity to MDR1 and MRP1-3. Thus, these SPECT tracers had different method for multidrug resistance prediction in this study. Additionally, [131I]adsterol was possibility to be higher accuracy multidrug resistance prediction method than [99mTc]sestamibi and [99mTc]tetrofosmin because [131I]adsterol had only affinity to BCRP.
|
